52648-13-2 Usage
Uses
Used in Pharmaceutical Industry:
3-(2-AMINO-ETHYL)-5-METHOXY-1H-INDOLE-2-CARBOXYLIC ACID is used as a potential therapeutic agent for the treatment of psychiatric disorders such as depression and anxiety. Its involvement in serotonin synthesis and activity makes it a promising candidate for the development of novel neuropharmaceuticals.
Used in Neurological Applications:
3-(2-AMINO-ETHYL)-5-METHOXY-1H-INDOLE-2-CARBOXYLIC ACID is used as a potential treatment for neurological disorders due to its potential role in modulating neurotransmitter activity and its antioxidant and anti-inflammatory properties.
Used in Antioxidant and Anti-inflammatory Applications:
3-(2-AMINO-ETHYL)-5-METHOXY-1H-INDOLE-2-CARBOXYLIC ACID is used as a potential antioxidant and anti-inflammatory agent, which may contribute to its therapeutic effects in various conditions, including psychiatric and neurological disorders.
Check Digit Verification of cas no
The CAS Registry Mumber 52648-13-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,2,6,4 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 52648-13:
(7*5)+(6*2)+(5*6)+(4*4)+(3*8)+(2*1)+(1*3)=122
122 % 10 = 2
So 52648-13-2 is a valid CAS Registry Number.
InChI:InChI=1/C12H14N2O3/c1-17-7-2-3-10-9(6-7)8(4-5-13)11(14-10)12(15)16/h2-3,6,14H,4-5,13H2,1H3,(H,15,16)
52648-13-2Relevant academic research and scientific papers
N6-Substituted Adenosine Receptor Agonists. Synthesis and Pharmacological Activity as Potent Antinociceptive Agents
Guengoer, Timur,Malabre, Patrice,Teulon, Jean-Marie,Camborde, Francoise,Meignen, Joelle,et al.
, p. 4307 - 4316 (2007/10/02)
Novel N6-(indol-3-yl)alkyl derivatives of adenosine were synthesized.The adenosine receptor affinity and the antinociceptive activity of these compounds were assessed in binding studies and the phenylbenzoquinone-induced writhing test.Most of these analogues exhibited a potent analgesic activity without side effects.Among them, compound 3c (UP 202-32) bound to A1 (Ki = 110 nM) and A2 (Ki = 350 nM) adenosine receptors in a specific manner since it did not interact with many other receptors, especially opioid binding sites.The antinociceptive activity in the phenylbenzoquinone assay (ED50 = 3.3 mg/kg po) was antagonized by 8-cyclopentyltheophylline, suggesting that an adenosinergic mechanism underlies the analgesic activity observed with this compound.The data obtained with these new N6-substituted adenosine receptor agonists emphasize the interest of such compounds in the treatment of pain.
